Abstracts tagged "quality improvement"

Abstract Number: 2508 • 2015 ACR/ARHP Annual Meeting
Adherence to ACR Guidelines in the Management of Lupus Nephritis – a Quality Improvement Initiative
Erik Anderson¹, Matthew Abramson¹, Sanjay Godhwani², Yaqi Xue³, Jie Yang³ and Heidi Roppelt⁴, ¹Internal Medicine, Stony Brook Hospital, Stony Brook, NY, ²Medicine/Rheumatology, Stony Brook Medicine, Setauket, NY, ³Stony Brook University, Stony Brook, NY, ⁴Rheumatology, SUNY Stony Brook Unversity Hospital, East Setauket, NY
Background/Purpose: Lupus nephritis not only decreases survival, but also its costs are substantial, likely due in part to deficits in care (Carls et al.,…
Abstract Number: 2541 • 2015 ACR/ARHP Annual Meeting
Improving Adherence with Treat to Target in Rheumatoid Arthritis through a Learning Collaborative: Rationale and Design of the Traction Trial
Daniel H. Solomon¹, Sara Lee², Agnes Zak², Jen Agosti³, Asaf Bitton⁴, Liana Fraenkel⁵, Leslie Harrold⁶, Elena Losina⁷, Bing Lu⁸, Theodore Pincus⁹, Josef S. Smolen¹⁰ and Jeffrey N. Katz¹¹, ¹Rheumatology, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³JRA Consulting, Andover, MA, ⁴Medicine, Brigham and Women's Hospital, Boston, MA, ⁵Medicine, Yale University School of Medicine, New Haven, CT, ⁶Dept of Medicine, UMass Medical School, Worcester, MA, ⁷Orthopedics, Brigham and Women's Hospital, BU School of Public Health and Harvard Medical School, Boston, MA, ⁸Rheumatology Immunology & Allergy, Brigham & Women's Hospital, Boston, MA, ⁹Medicine-Rheumatology, NYU Hospital for Joint Diseases, New York, NY, ¹⁰Medical University of Vienna, Vienna, Austria, ¹¹Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Treat to target (TTT) is a recommended paradigm in the management of rheumatoid arthritis (RA). However, various data sources suggest that TTT is…
Abstract Number: 2699 • 2014 ACR/ARHP Annual Meeting
Optimizing Scleroderma Centers of Excellence: Perspectives from Patients and Scleroderma (SSc) Experts
Veronika K. Jaeger¹, Andrew Aubin², Nancy Baldwin³, Kim Fligelstone⁴, Robyn Sims⁵, Joep Welling⁶, Ryan Burrill⁷, Kerri Connolly⁷, Tracy Frech⁸, Jessica K. Gordon⁹, Tanaka Ngcozana¹⁰, Monika Kowalczyk¹¹, Matthew R. Lammi¹², Ulrich A. Walker¹ and Lesley Ann Saketkoo¹³, ¹Department of Rheumatology, University Hospital Basel, Basel, Switzerland, Basel, Switzerland, ²Louisiana State University School of Medicine, New Orleans, LA, ³Scleroderma Foundation - Chicago Support Group, Chicago, IL, ⁴Royal Free Hospital, Scleroderma Unit and Scleroderma Society, London, United Kingdom, ⁵Scleroderma Australia, Victoria, Australia, ⁶The Dutch Patient Organization for Systemic Autoimmune Diseases, Utrecht, Netherlands, ⁷Scleroderma Foundation, Boston, MA, ⁸Div of Rheumatology, University of Utah, Salt Lake City, UT, ⁹Rheumatology, Hospital for Special Surgery, New York, NY, ¹⁰Rheumatology Department, Lower, Royal Free hospital, London, United Kingdom, ¹¹DIvision of Gastroenterology, Tulane University School of Medicine, New Orleans, LA, ¹²Louisiana State University Health Sciences Center, Pulmonary and Critical Medicine, New Orleans, LA, ¹³Scleroderma and Sarcoidosis Patient Care and Research Center, Rheumatology and Pulmonary Medicine, Louisiana State University Health Sciences Center, New Orleans, LA
Background/Purpose: SSc is a complex, diffuse, devastating health condition of vascular injury, inflammation and fibrosis resulting in multiple organ-system derangements with high impact on…
Abstract Number: 1830 • 2014 ACR/ARHP Annual Meeting
A Novel Population Care Model in Rheumatoid Arthritis – Significant Improvement in Quality and Reduction in Cost of Care
Eric D. Newman¹, William T. Ayoub², David M. Pugliese³, Chelsea Cedeno⁴, Jason Brown⁵, Thomas M. Harrington⁶, Thomas P. Olenginski⁶, Androniki Bili⁷, Alfred E. Denio⁶, Lisa L. Schroeder⁷, Dennis Torretti⁷, Tarun Sharma⁷, Lyudmila Kirillova⁷, Susan Mathew⁷, Jonida Cote⁷, Brian Oppermann², Cynthia Sullivan², Shantanu Bishwal⁸, Brian DelVecchio³ and Howard Aylward⁹, ¹Department of Rheumatology, Geisinger Health System, Danville, PA, ²Rheumatology, Geisinger Health System, State College, PA, ³Rheumatology, Geisinger Health System, Wilkes-Barre, PA, ⁴Division of Medicine, Geisinger Medical Center, Geisinger Health System, Danville, PA, ⁵Henry Hood Center for Clinical Research, Geisinger Health System, Danville, PA, ⁶Dept of Rheumatology, Geisinger Health System, Danville, PA, ⁷Rheumatology, Geisinger Health System, Danville, PA, ⁸Rheumatology, Geisinger Health System, Wilkes Barre, PA, ⁹Geisinger Health System, State College, PA
Background/Purpose: Rheumatoid arthritis (RA) is a common chronic disease with significant morbidity, mortality, and cost. To optimize care for RA patients, we developed a novel…
Abstract Number: 1348 • 2014 ACR/ARHP Annual Meeting
Improvement in Herpes Zoster Vaccination and Documentation for Rheumatoid Arthritis Patients Using Electronic Medical Record
Heena Sheth¹, Siamak Moghadam-Kia¹, Rayford June², Hilary J. Peterson¹, Davi Sa Leitao³, Larry W. Moreland⁴ and Rohit Aggarwal¹, ¹Medicine, University of Pittsburgh, Pittsburgh, PA, ²Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ³Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁴Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Despite increased risk of herpes zoster (HZ) in rheumatoid arthritis (RA) patients on immunosuppressive medication, American College of Rheumatology guidelines on HZ vaccination in…
Abstract Number: 1344 • 2014 ACR/ARHP Annual Meeting
Electronic Medical Record-Based Best Practice Alert Used By Clinical Staff Improved Pneumococcal Vaccination and Documentation Among Immunosuppressed Rheumatoid Arthritis Patients
Heena Sheth¹, Larry W. Moreland², Hilary J. Peterson¹ and Rohit Aggarwal¹, ¹Medicine, University of Pittsburgh, Pittsburgh, PA, ²Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The Centers for Disease Control and American College of Rheumatology guidelines recommend pneumococcal vaccination for all immunosuppressed patients, specifically those taking disease modifying antirheumatic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].